2/4/2002

Novartis Pharmaceutical's Gleevec has been approved for use in treating gastrointestinal stromal cancer. The disease, a rare form of cancer, affects about 5,000 people in the U.S. Gleevec was first approved by the FDA in May for the treatment of chronic myeloid leukemia.

Related Summaries